Cleared Traditional

K251563 - WELLlife Flu A&B Home Test (FDA 510(k) Clearance)

Also includes:
WELLlife Influenza A&B Test
Aug 2025
Decision
90d
Days
Class 2
Risk

K251563 is an FDA 510(k) clearance for the WELLlife Flu A&B Home Test. This device is classified as a Multi-analyte Respiratory Virus Antigen Detection Test (Class II - Special Controls, product code SCA).

Submitted by Wondfo USA Co., Ltd. (San Diego, US). The FDA issued a Cleared decision on August 20, 2025, 90 days after receiving the submission on May 22, 2025.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3987. A Multi-analyte Respiratory Virus Antigen Detection Test Is An In Vitro Diagnostic Device Intended For The Detection And/or Differentiation Of Respiratory Viruses Directly From Respiratory Clinical Specimens. The Device Is Intended To Be Performed At The Site Of Sample Collection, Does Not Involve Sample Storage And/or Transport..

Submission Details

510(k) Number K251563 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received May 22, 2025
Decision Date August 20, 2025
Days to Decision 90 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code SCA - Multi-analyte Respiratory Virus Antigen Detection Test
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3987
Definition A Multi-analyte Respiratory Virus Antigen Detection Test Is An In Vitro Diagnostic Device Intended For The Detection And/or Differentiation Of Respiratory Viruses Directly From Respiratory Clinical Specimens. The Device Is Intended To Be Performed At The Site Of Sample Collection, Does Not Involve Sample Storage And/or Transport.